Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Active, not recruiting · NCT03863184 · Registry updated 2026-04-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL | Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-04-28 | NCT03863184 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Celgene Corporation | 20 |
| Weill Medical College of Cornell University | 276 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Weill Cornell Medicine | New York | United States | 122 |